Characterization and management of mobocertinib (TAK-788) induced skin toxicity in patients with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) who previously received platinum chemotherapy

被引：1
|
作者：
Yang, J. C-H. [1 ]
Ramalingam, S. S. [2 ]
Kim, T. M. [3 ]
Kim, S-W. [4 ]
Riely, G. J. [5 ]
Mekhail, T. [6 ]
Nguyen, D. [7 ]
Campelo, M. R. Garcia [8 ]
Felip, E. [9 ]
Bazhenova, L. [10 ]
Jin, S. [11 ,12 ]
Griffin, C. [13 ]
Bunn, V. [12 ,14 ]
Lin, J. [12 ,15 ]
Churchill, E. N. [12 ,16 ]
Mehta, M. [11 ,12 ]
Janne, P. A. [17 ]
Zhou, C. [18 ]
机构：
[1] Natl Taiwan Univ, Ctr Canc, Dept Med Oncol, Taipei, Taiwan
[2] Emory Univ, Winship Canc Inst, Hematol & Med Oncol Dept, Atlanta, GA USA
[3] Seoul Natl Univ Hosp, Dept Hematooncol, Seoul, South Korea
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[5] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
[6] AdventHlth Orlando, Thorac Canc Program, Orlando, FL USA
[7] Pacific Shores Med Grp, Hematol Oncol, Long Beach, CA USA
[8] Univ Hosp A Coruna, CHUAC, Dept Med Oncol, La Coruna, Spain
[9] Vall Hebron Univ Hosp, Med Oncol Serv, Lung Canc Unit, Barcelona, Spain
[10] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
[11] Millennium Pharmaceut Inc, Clin Sci, Oncol, Cambridge, MA USA
[12] Takeda Pharmaceut Co Ltd, Cambridge, MA USA
[13] Millennium Pharmaceut Inc, Global Patient Safety Evaluat, Cambridge, MA USA
[14] Millennium Pharmaceut Inc, Stat, Cambridge, MA USA
[15] Millennium Pharmaceut Inc, Oncol Stat, Cambridge, MA USA
[16] Millennium Pharmaceut Inc, Global Med Affairs Oncol, Cambridge, MA USA
[17] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[18] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1836
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1231P
引用
收藏
页码：S975 / S975
页数：1
相关论文
共 50 条
  • [1] Characterization of GI toxicities and their impact on efficacy in patients (pts) with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) treated with mobocertinib (TAK-788) who previously received platinum chemotherapy
    Nguyen, D.
    Ramalingam, S. S.
    Spira, A.
    Riely, G. J.
    Kim, T. M.
    Yang, J. C-H.
    Piotrowska, Z.
    Campelo, M. R. Garcia
    Felip, E.
    Bazhenova, L.
    Jin, S.
    Griffin, C.
    Diderichsen, P. M.
    Gupta, N.
    Bunn, V.
    Lin, J.
    Churchill, E. N.
    Mehta, M.
    Zhou, C.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S968 - S969
  • [2] Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer
    Gonzalvez, Francois
    Vincent, Sylvie
    Baker, Theresa E.
    Gould, Alexandra E.
    Li, Shuai
    Wardwell, Scott D.
    Nadworny, Sara
    Ning, Yaoyu
    Zhang, Sen
    Huang, Wei-Sheng
    Hu, Yongbo
    Li, Feng
    Greenfield, Matthew T.
    Zech, Stephan G.
    Das, Biplab
    Narasimhan, Narayana, I
    Clackson, Tim
    Dalgarno, David
    Shakespeare, William C.
    Fitzgerald, Michael
    Chouitar, Johara
    Griffin, Robert J.
    Liu, Shengwu
    Wong, Kwok-Kin
    Zhu, Xiaotian
    Rivera, Victor M.
    CANCER DISCOVERY, 2021, 11 (07) : 1672 - 1687
  • [3] Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer
    Yang, James Chih-Hsin
    Zhou, Caicun
    Janne, Pasi A.
    Ramalingam, Suresh S.
    Kim, Tae Min
    Riely, Gregory J.
    Spira, Alexander, I
    Piotrowska, Zofia
    Mekhail, Tarek
    Campelo, Maria Rosario Garcia
    Felip, Enriqueta
    Bazhenova, Lyudmila
    Jin, Shu
    Kaur, Manmit
    Diderichsen, Paul M.
    Gupta, Neeraj
    Bunn, Veronica
    Lin, Jianchang
    Churchill, Eric
    Mehta, Minal
    Nguyen, Danny
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (01) : 95 - 106
  • [4] Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial
    Riely, Gregory J.
    Neal, Joel W.
    Camidge, D. Ross
    Spira, Alexander, I
    Piotrowska, Zofia
    Costa, Daniel B.
    Tsao, Anne S.
    Patel, Jyoti D.
    Gadgeel, Shirish M.
    Bazhenova, Lyudmila
    Zhu, Viola W.
    West, Howard L.
    Mekhail, Tarek
    Gentzler, Ryan D.
    Nguyen, Danny
    Vincent, Sylvie
    Zhang, Steven
    Lin, Jianchang
    Bunn, Veronica
    Jin, Shu
    Li, Shuanglian
    Janne, Pasi A.
    CANCER DISCOVERY, 2021, 11 (07) : 1688 - 1699
  • [5] Mobocertinib (TAK-788) as first-line treatment vs platinum-based chemotherapy (CT) for NSCLC with EGFR exon 20 insertions (exon20ins)
    Janne, P. A.
    Wu, Y-L.
    Kato, T.
    Besse, B.
    Peters, S.
    Nguyen, D.
    Berg, D.
    Lin, J.
    Feng, Z.
    Mok, T.
    ANNALS OF ONCOLOGY, 2020, 31 : S892 - S893
  • [6] Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic non-small cell lung cancer (mNSCLC): Treatment (tx) beyond progressive disease (PD) in platinum-pretreated patients (pts) with and without intracranial PD.
    Janne, Pasi A.
    Ramalingam, Suresh S.
    Yang, James Chih-Hsin
    Riely, Gregory J.
    Bunn, Veronica
    Jin, Shu
    Zhou, Caicun
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Mobocertinib (TAK-788) in metastatic EGFR Exon 20 Insertions (ex20ins) + NSCLC: Results of platinum-experienced Patients and the EXCLAIM Cohort of a Phase 1/2 Study
    Misch, D.
    Ramalingam, S.
    Zhou, C.
    Kim, T. M.
    Yang, J. C.
    Riely, G.
    Mekhail, T.
    Nguyen, D.
    Campelo, Garcia M. R.
    Felip, E.
    Bunn, V.
    Lin, H.
    Zhang, P.
    Jaenne, P.
    Kaur, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 96 - 97
  • [8] Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial (vol 11, pg 1688, 2021)
    Riely, G. J.
    Neal, J. W.
    Camidge, D. R.
    Spira, A., I
    Piotrowska, Z.
    Costa, D. B.
    CANCER DISCOVERY, 2023, 13 (09) : 2107 - 2107
  • [9] Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study.
    Ramalingam, Suresh S.
    Zhou, Caicun
    Kim, Tae Min
    Kim, Sang-We
    Yang, James Chih-Hsin
    Riely, Gregory J.
    Mekhail, Tarek
    Nguyen, Danny
    Campelo, Maria Rosario Garcia
    Felip, Enriqueta
    Vincent, Sylvie
    Jin, Shu
    Bunn, Veronica
    Lin, Jianchang
    Lin, Huamao Mark
    Mehta, Minal
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Mechanisms of resistance to mobocertinib in EGFR exon 20 insertion-mutant non-small cell lung cancer (NSCLC)
    Park, S.
    Kim, T. M.
    Kim, S.
    Kim, M.
    Keam, B.
    Kim, D. W.
    Heo, D. S.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S110 - S111
12345